Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

SentinelOne is making a major push this year around AI-powered SIEM, as well as cloud and data security, Channel Chief Brian ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

We recently published a list of 10 Best Software Infrastructure Stocks to Buy According to Analysts. In this article, we are ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE).

From that perspective, Palo Alto Networks trades at essentially half the valuation of CrowdStrike.

It can be difficult to fully appreciate just what has changed when it comes to cybersecurity – and by how much. Up until around two decades ago, the network was the definitive perimeter of cyber ...

BlackBerry acquired Cylance, which harnesses artificial intelligence (AI) to help power its security offerings, in 2019. That deal saw it pay $1.4 billion in cash, in addition to unvested employee ...